Francesca Ricci

TL;DR: Evidence is presented that MRP1, but not P-gp, expression is under the control of the PI3K/Akt axis in AML blasts, and data suggest that PI3k/AKT activation may lead to the development of chemoresistance inAML blasts through a mechanism involving a p53-dependent suppression of MRP 1 expression.

TL;DR: The findings indicate that perifosine, either alone or in combination with existing drugs, might be a promising therapeutic agent for the treatment of those AML cases characterized by upregulation of the PI3K–Akt survival pathway.

TL;DR: A molecular signature representative of the transcriptional abnormalities of BPDCN is identified and a cellular model proposing a novel therapeutic approach in the setting of this otherwise incurable disease is developed.

TL;DR: A panel of patient-derived EOC xenografts that recapitulate the recently type I and type II classification serves to study the biology of ovarian cancer, identify tumor-specific molecular markers, and develop novel treatment modalities.

TL;DR: In vivo treatment of mice bearing OVCAR-5 xenografts with the combination of Chk1 and Wee1 inhibitors led to greater tumor growth inhibition than with the inhibitors used as single agents with no toxicity, providing a strong rationale for the clinical investigation of the combined treatment.